RU2004124047A - Композиция, ингибирующая матричные металлопротеиназы, предназначенная для лечения неопластических болезней - Google Patents
Композиция, ингибирующая матричные металлопротеиназы, предназначенная для лечения неопластических болезней Download PDFInfo
- Publication number
- RU2004124047A RU2004124047A RU2004124047/15A RU2004124047A RU2004124047A RU 2004124047 A RU2004124047 A RU 2004124047A RU 2004124047/15 A RU2004124047/15 A RU 2004124047/15A RU 2004124047 A RU2004124047 A RU 2004124047A RU 2004124047 A RU2004124047 A RU 2004124047A
- Authority
- RU
- Russia
- Prior art keywords
- matrix metalloproteinase
- group
- composition
- antioxidant
- catechin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 21
- 201000010099 disease Diseases 0.000 title claims abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 5
- 230000001613 neoplastic effect Effects 0.000 title claims abstract 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title claims 10
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title claims 10
- 230000002401 inhibitory effect Effects 0.000 title claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract 31
- 238000000034 method Methods 0.000 claims abstract 22
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract 17
- 239000011668 ascorbic acid Substances 0.000 claims abstract 16
- 229960005070 ascorbic acid Drugs 0.000 claims abstract 11
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract 11
- 235000005487 catechin Nutrition 0.000 claims abstract 11
- 229950001002 cianidanol Drugs 0.000 claims abstract 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract 5
- 239000004472 Lysine Substances 0.000 claims abstract 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract 5
- -1 catechin compound Chemical class 0.000 claims abstract 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 14
- 239000003963 antioxidant agent Substances 0.000 claims 12
- 230000003078 antioxidant effect Effects 0.000 claims 12
- 235000006708 antioxidants Nutrition 0.000 claims 12
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims 9
- 235000019152 folic acid Nutrition 0.000 claims 9
- 239000011724 folic acid Substances 0.000 claims 9
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 6
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 6
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims 6
- 229940030275 epigallocatechin gallate Drugs 0.000 claims 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 6
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 6
- 229910052711 selenium Inorganic materials 0.000 claims 6
- 239000011669 selenium Substances 0.000 claims 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 5
- 229940072107 ascorbate Drugs 0.000 claims 5
- 229960000304 folic acid Drugs 0.000 claims 5
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims 4
- 229940014144 folate Drugs 0.000 claims 4
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims 3
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 claims 3
- TVLSKGDBUQMDPR-UHFFFAOYSA-N 2,3-Dimethoxy-5-methyl-6-(3-methyl-2-buten-1-yl)-1,4-benzenediol Chemical class COC1=C(O)C(C)=C(CC=C(C)C)C(O)=C1OC TVLSKGDBUQMDPR-UHFFFAOYSA-N 0.000 claims 3
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims 3
- 108010024636 Glutathione Proteins 0.000 claims 3
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims 3
- 229940093797 bioflavonoids Drugs 0.000 claims 3
- 229960004203 carnitine Drugs 0.000 claims 3
- 235000021466 carotenoid Nutrition 0.000 claims 3
- 150000001747 carotenoids Chemical class 0.000 claims 3
- 235000012734 epicatechin Nutrition 0.000 claims 3
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims 3
- 229960003180 glutathione Drugs 0.000 claims 3
- 235000003969 glutathione Nutrition 0.000 claims 3
- 235000019136 lipoic acid Nutrition 0.000 claims 3
- 235000018977 lysine Nutrition 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 235000013930 proline Nutrition 0.000 claims 3
- 229940082569 selenite Drugs 0.000 claims 3
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 claims 3
- 229960002663 thioctic acid Drugs 0.000 claims 3
- 229930003799 tocopherol Natural products 0.000 claims 3
- 239000011732 tocopherol Substances 0.000 claims 3
- 125000002640 tocopherol group Chemical class 0.000 claims 3
- 235000019149 tocopherols Nutrition 0.000 claims 3
- 229930003802 tocotrienol Natural products 0.000 claims 3
- 239000011731 tocotrienol Substances 0.000 claims 3
- 229940068778 tocotrienols Drugs 0.000 claims 3
- 235000019148 tocotrienols Nutrition 0.000 claims 3
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 claims 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 claims 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 claims 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims 1
- 102000004318 Matrilysin Human genes 0.000 claims 1
- 108090000855 Matrilysin Proteins 0.000 claims 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims 1
- 108010076497 Matrix Metalloproteinase 10 Proteins 0.000 claims 1
- 102000011723 Matrix Metalloproteinase 11 Human genes 0.000 claims 1
- 108010076502 Matrix Metalloproteinase 11 Proteins 0.000 claims 1
- 108010076501 Matrix Metalloproteinase 12 Proteins 0.000 claims 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 claims 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 claims 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 102100030416 Stromelysin-1 Human genes 0.000 claims 1
- 102100028848 Stromelysin-2 Human genes 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
Claims (36)
1. Композиция, содержащая катехин, антиоксидант, пролин и лизин, эффективная при ингибировании матричной металлопротеиназы.
2. Композиция по п.1, в которой катехин выбирают из группы, состоящей из эпикатехинов, эпигаллокатехина, эпикатехингаллата и эпигаллокатехингаллата.
3. Композиция по п.1, в которой катехин представляет собой эпигаллокатехингаллат.
4. Композиция по п.1, в которой антиоксидант выбирают из группы, состоящей из аскорбиновой кислоты, токоферолов, токотриенолов, каротиноидов, глутатиона, альфа-липоевой кислоты, убихинолов, биофлавоноидов и карнитина.
5. Композиция по п.1, в которой антиоксидант представляет собой аскорбиновую кислоту.
6. Композиция по п.5, в которой аскорбиновую кислоту выбирают из группы, состоящей из предшественников аскорбатов, метаболитов аскорбатов и аскорбата соли.
7. Композиция по п.1, в которой антиоксидант также содержит фолиевую кислоту.
8. Композиция по п.8, в которой фолиевая кислота является фолатом.
9. Композиция по п.1, содержащая селен.
10. Композиция по п.9, в которой селен выбирают из группы, состоящей из селенита и метилселината.
11. Композиция по п.1, в которой матричную металлопротеиназу выбирают из группы, состоящей из матричной металлопротеиназы 1, матричной металлопротеиназы 2, матричной металлопротеиназы 3, матричной металлопротеиназы 4, матричной металлопротеиназы 5, матричной металлопротеиназы 6, матричной металлопротеиназы 7, матричной металлопротеиназы 8, матричной металлопротеиназы 9, матричной металлопротеиназы 10, матричной металлопротеиназы 11, матричной металлопротеиназы 12 и матричной металлопротеиназы 14.
12. Композиция по п.1, в которой матричной металлопротеиназой является матричная металлопротеиназа 2.
13. Композиция по п.1, в которой матричной металлопротеиназой является матричная металлопротеиназа 9.
14. Способ лечения болезней человека, связанных с повышенной матричной металлопротеиназной активностью, включающий введение нуждающемуся в этом пациенту композиции, содержащей катехин, антиоксидант, пролин и лизин, эффективной при ингибировании матричной металлопротеиназы.
15. Способ по п.14, согласно которому катехин выбирают из группы, состоящей из эпикатехинов, эпигаллокатехина, эпикатехингаллата и эпигаллокатехингаллата.
16. Способ по п.14, согласно которому катехин представляет собой эпигаллокатехингаллат.
17. Способ по п.14, согласно которому антиоксидант выбирают из группы, состоящей из аскорбиновой кислоты, токоферолов, токотриенолов, каротиноидов, глутатиона, альфа-липоевой кислоты, убихинолов, биофлавоноидов и карнитина.
18. Способ по п.14, согласно которому антиоксидант представляет собой аскорбиновую кислоту.
19. Способ по п.14, согласно которому аскорбиновая кислота также включает аскорбат, выбранный из группы, состоящей из предшественников аскорбатов, метаболитов аскорбатов и аскорбатов солей.
20. Способ по п.14, согласно которому антиоксидант также содержит фолиевую кислоту.
21. Способ по п.20, согласно которому фолиевой кислотой является фолат.
22. Способ по п.14, согласно которому композиция содержит селен.
23. Способ по п.14, согласно которому селен выбирают из группы, состоящей из селенита и метилселината.
24. Способ по п.14, согласно которому болезнь человека выбирают из группы, состоящей из неопластических состояний, воспалительных заболеваний, инфекционных заболеваний, сердечно-сосудистых заболеваний, дегенеративных болезней, неврологических болезней и аутоиммунных болезней.
25. Способ лечения неопластических заболеваний, связанных с чрезмерным разрушением внеклеточного матрикса, включающий введение эффективного количества композиции, содержащей катехин, антиоксидант, пролин и лизин.
26. Способ по п.25, согласно которому катехин выбирают из группы, состоящей из эпикатехинов, эпигаллокатехина, эпикатехингаллата и эпигаллокатехингаллата.
27. Способ по п.25, согласно которому катехин представляет собой эпигаллокатехингаллат.
28. Способ по п.25, согласно которому антиоксидант выбирают из группы, состоящей из аскорбиновой кислоты, токоферолов, токотриенолов, каротиноидов, глутатиона, альфа-липоевой кислоты, убихинолов, биофлавоноидов и карнитина.
29. Способ по п.25, согласно которому антиоксидант представляет собой аскорбиновую кислоту.
30. Способ по п.25, согласно которому аскорбиновая кислота также включает предшественников аскорбатов, метаболиты аскорбатов и аскорбат соль.
31. Способ по п.25, согласно которому антиоксидант также содержит фолиевую кислоту.
32. Способ по п.31, согласно которому фолиевой кислотой является фолат.
33. Способ по п.25, согласно которому композиция содержит селен.
34. Способ по п.33, согласно которому селен выбирают из группы, состоящей из селенита и метилселината.
35. Фармацевтический препарат, включающий композицию по любому из пп.1-13.
36. Фармацевтический препарат по п.35, предназначенный для перорального введения, парентерального введения или местного нанесения.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/041,427 US6939860B2 (en) | 2002-01-08 | 2002-01-08 | Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| US10/041,427 | 2002-01-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004124047A true RU2004124047A (ru) | 2005-04-20 |
| RU2284185C2 RU2284185C2 (ru) | 2006-09-27 |
Family
ID=21916454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004124047/15A RU2284185C2 (ru) | 2002-01-08 | 2002-01-31 | Композиция, ингибирующая матричные металлопротеиназы, предназначенная для лечения неопластических болезней |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US6939860B2 (ru) |
| EP (1) | EP1463498B1 (ru) |
| JP (1) | JP4144800B2 (ru) |
| KR (1) | KR20050005408A (ru) |
| CN (1) | CN1612731A (ru) |
| AT (1) | ATE439833T1 (ru) |
| AU (2) | AU2002244690A1 (ru) |
| BR (1) | BR0208052A (ru) |
| CA (1) | CA2469162A1 (ru) |
| CZ (1) | CZ2004853A3 (ru) |
| DE (1) | DE60233433D1 (ru) |
| EE (1) | EE200400031A (ru) |
| ES (1) | ES2332126T3 (ru) |
| HR (1) | HRP20040705A2 (ru) |
| HU (1) | HUP0402421A3 (ru) |
| IL (1) | IL162384A0 (ru) |
| LT (1) | LT5215B (ru) |
| LV (1) | LV13249B (ru) |
| MX (1) | MXPA04006627A (ru) |
| NO (1) | NO20033949L (ru) |
| NZ (1) | NZ533353A (ru) |
| PL (1) | PL371205A1 (ru) |
| RU (1) | RU2284185C2 (ru) |
| SI (1) | SI21871A (ru) |
| SK (1) | SK2772004A3 (ru) |
| TR (1) | TR200401669T1 (ru) |
| UA (1) | UA78979C2 (ru) |
| WO (1) | WO2003057211A1 (ru) |
| ZA (1) | ZA200404915B (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8669282B2 (en) * | 2000-10-31 | 2014-03-11 | Hill's Pet Nutrition, Inc. | Companion animal compositions including lipoic acid and methods of use thereof |
| US6939860B2 (en) * | 2002-01-08 | 2005-09-06 | Matthias Rath | Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| US20050079234A1 (en) * | 2003-08-27 | 2005-04-14 | Chiang Yang Chi | Compositions comprising herbs and method for immunomodulation |
| KR20050070385A (ko) * | 2003-12-30 | 2005-07-07 | (주)현덕비엔티 | 폴리페놀과, 아스코르빈산 또는 그 유도체를 함유하는항암치료 보조용 조성물 |
| WO2006053184A2 (en) * | 2004-11-10 | 2006-05-18 | The Trustees Of Columbia University In The City Of New York | Methods for treating or preventing a vascular disease |
| ES2246737B1 (es) * | 2005-06-09 | 2006-12-01 | Jose Juan Rodriguez Jerez | "composicion farmaceutica que comprende lisina y usos correspondientes". |
| ES2497766T3 (es) * | 2005-12-29 | 2014-09-23 | Mitsui Norin Co., Ltd | Composiciones y procedimientos de sensibilizar a oxacilina Staphylococcus aureus resistente a meticilina |
| US20070265211A1 (en) * | 2006-05-12 | 2007-11-15 | Matthias Rath | Novel composition and method effective in inhibiting the atherogenic process |
| US20100055205A1 (en) * | 2008-08-29 | 2010-03-04 | Kristina Mains | Functional consumable compositions for promoting skin health and methods for using the same |
| EP2179722A1 (en) * | 2008-10-24 | 2010-04-28 | Heinrich-Pette-Institut für experimentelle Virologie und Immunologie | Topical formation for preventing sexual transmission of viral infection |
| WO2010053833A1 (en) | 2008-11-04 | 2010-05-14 | Vymedic, Llc | Antiviral supplement formulations |
| EP2489653B1 (en) * | 2009-10-16 | 2017-11-29 | Kaneka Corporation | Method for producing reduced coenzyme q10 and composition comprising same |
| EP2649994B1 (de) | 2011-01-31 | 2017-08-30 | LUCOLAS-M.D. Ltd. | Kombinationen von aromatase inhibitoren und antioxidanzien |
| KR101829330B1 (ko) | 2011-04-13 | 2018-02-20 | (주)아모레퍼시픽 | 염증성 피부 노화 억제 물질 스크리닝 방법 |
| CN102526170B (zh) * | 2011-12-31 | 2015-04-29 | 许学志 | 抗结核杆菌的儿茶提取物组合物、其制备方法及含有它们的药物制剂和应用 |
| BE1023772B9 (fr) * | 2013-05-17 | 2017-08-02 | Valore | Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer |
| CN104096058A (zh) * | 2014-07-02 | 2014-10-15 | 胥玲 | 一种治疗扩张型心肌病的中药药丸 |
| BE1022579A9 (fr) * | 2014-11-10 | 2016-10-06 | Valore | Composition antimétastatique comprenant au moins un composé de type flavanol |
| WO2024003061A1 (en) * | 2022-06-30 | 2024-01-04 | Lo.Li. Pharma S.R.L. | Composition for the treatment of the human papillomavirus infection (hpv) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962517A (en) * | 1997-01-31 | 1999-10-05 | Murad; Howard | Pharmaceutical compositions and methods for treating acne |
| US5817695A (en) * | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
| CA2377414A1 (en) | 1999-06-15 | 2000-12-21 | John D. Potter | Nutrient formulations for disease reduction, and related treatment and component screening methods |
| US6939860B2 (en) * | 2002-01-08 | 2005-09-06 | Matthias Rath | Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| ES2299689T3 (es) * | 2002-02-25 | 2008-06-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Compuestos de cicloalquil-uera fusionada con benzo 1,4-disustituido, utiles para el tratamiento de enfermedades por citoquinas. |
-
2002
- 2002-01-08 US US10/041,427 patent/US6939860B2/en not_active Expired - Fee Related
- 2002-01-31 PL PL02371205A patent/PL371205A1/xx unknown
- 2002-01-31 KR KR10-2004-7010603A patent/KR20050005408A/ko not_active Application Discontinuation
- 2002-01-31 HU HU0402421A patent/HUP0402421A3/hu unknown
- 2002-01-31 CZ CZ2004853A patent/CZ2004853A3/cs unknown
- 2002-01-31 IL IL16238402A patent/IL162384A0/xx not_active IP Right Cessation
- 2002-01-31 AT AT02712877T patent/ATE439833T1/de active
- 2002-01-31 CA CA002469162A patent/CA2469162A1/en not_active Abandoned
- 2002-01-31 TR TR2004/01669T patent/TR200401669T1/xx unknown
- 2002-01-31 SI SI200220038A patent/SI21871A/sl not_active IP Right Cessation
- 2002-01-31 RU RU2004124047/15A patent/RU2284185C2/ru not_active IP Right Cessation
- 2002-01-31 CN CNA028269543A patent/CN1612731A/zh active Pending
- 2002-01-31 MX MXPA04006627A patent/MXPA04006627A/es active IP Right Grant
- 2002-01-31 UA UA20040705480A patent/UA78979C2/uk unknown
- 2002-01-31 BR BR0208052-4A patent/BR0208052A/pt not_active IP Right Cessation
- 2002-01-31 WO PCT/EP2002/001005 patent/WO2003057211A1/en active IP Right Grant
- 2002-01-31 ES ES02712877T patent/ES2332126T3/es not_active Expired - Lifetime
- 2002-01-31 EE EEP200400031A patent/EE200400031A/xx unknown
- 2002-01-31 DE DE60233433T patent/DE60233433D1/de not_active Expired - Lifetime
- 2002-01-31 NZ NZ533353A patent/NZ533353A/en unknown
- 2002-01-31 AU AU2002244690A patent/AU2002244690A1/en not_active Abandoned
- 2002-01-31 SK SK277-2004A patent/SK2772004A3/sk not_active Application Discontinuation
- 2002-01-31 EP EP02712877A patent/EP1463498B1/en not_active Expired - Lifetime
- 2002-01-31 JP JP2003557569A patent/JP4144800B2/ja not_active Expired - Fee Related
-
2003
- 2003-09-05 NO NO20033949A patent/NO20033949L/no not_active Application Discontinuation
-
2004
- 2004-06-22 ZA ZA200404915A patent/ZA200404915B/en unknown
- 2004-08-03 HR HR20040705A patent/HRP20040705A2/hr not_active Application Discontinuation
- 2004-08-05 LT LT2004074A patent/LT5215B/lt unknown
- 2004-09-06 LV LVP-04-88A patent/LV13249B/en unknown
- 2004-09-15 US US10/942,723 patent/US20050032715A1/en not_active Abandoned
-
2005
- 2005-08-24 US US11/211,389 patent/US20050281794A1/en not_active Abandoned
-
2008
- 2008-07-16 AU AU2008203157A patent/AU2008203157A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004124047A (ru) | Композиция, ингибирующая матричные металлопротеиназы, предназначенная для лечения неопластических болезней | |
| HUP0500498A2 (hu) | Rák kezelésére alkalmazható polifenolokat tartalmazó táplálék gyógyszerkészítmény | |
| EA200800056A1 (ru) | Каннабиноидный активный фармацевтический ингредиент для лекарственных форм | |
| US20100330171A1 (en) | Dietary Supplement for Eye Health | |
| RU2015138442A (ru) | Антиоксидантные композиции и способы их применения | |
| BR0315580A (pt) | Derivados de metileno uréia | |
| BR0211228A (pt) | Composto, composição farmacêutica e seus usos | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| DE502004011581D1 (de) | Verwendung von rotigotin zur behandlung von depressionen | |
| KR20070108382A (ko) | 항암성 화합물 | |
| RS54050B1 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS | |
| EP1351679B1 (en) | Method and composition for the treatment of diabetic neuropathy | |
| UA92498C2 (ru) | Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм | |
| TW200501963A (en) | Pharmaceutical compositions comprising epinastine for the treatment of skin diseases | |
| BRPI0411702A (pt) | uso de ácido hialurÈnico para preparar composições para o tratamento de aftas da cavidade oral | |
| AR045912A1 (es) | Composiciones farmaceuticas que contienen derivados de azetidina | |
| US20020165207A1 (en) | Compositions and methods for the treatment of diabetic neuropathy | |
| BRPI0412453A (pt) | uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo | |
| WO2006108430A1 (en) | Nutrient composition comprising green tea polyphenols for treating osteosarcoma | |
| BR0114339A (pt) | Composições farmaceuticamente aceitáveis contendo epinastina e pseudoefedrina | |
| BE1020183A3 (nl) | Farmaceutische samenstelling voor gebruik bij de behandeling en preventie van gingivitis en parodontitis. | |
| RU2005141423A (ru) | Пищевые композиции и способ ингибирования ими сокращения гладкомышечной клетки | |
| Sana | GREEN TEA: TRIVIAL TO IMPERATIVE. | |
| RU2007127861A (ru) | Композиция для ухода за полостью рта, содержащая экстракт неокисленной camellia | |
| BR0214644A (pt) | Uso de derivados de ácido 4-oxobutanóico no tratamento de inflamação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20090201 |